(Total Views: 303)
Posted On: 07/11/2019 9:51:48 AM
Post# of 152952
I know several of these have been discussed individually, but if anyone has time, it would be nice to draft a single post with the CCR5 antagonists (competition) to show:
1) Targeted indication/s and what phase they currently in
2) MOA (how they differ from each other)
3) Efficacy
4) SAEs
Based on yesterday's article I see these listed as the CCR5 antagonists retasked in cancer:
1) Maraviroc
2) Vicriviroc
3) Leronlimab
4) TAK-779
5) Anibamine
6) Met-CCL5
7) Aplaviroc (discontinued due to hepatotoxicity)
saponin or DT-13
9) siRNA and zinc finger nuclease (ZFN)
10) OTR4120 & OTR4131
11) INCB9471 (discontinued after P2 trial for HIV)
12) Cinicriviroc or TBR-652 (completed Phase IIb for HIV and currently being tested in NASH)
1) Targeted indication/s and what phase they currently in
2) MOA (how they differ from each other)
3) Efficacy
4) SAEs
Based on yesterday's article I see these listed as the CCR5 antagonists retasked in cancer:
1) Maraviroc
2) Vicriviroc
3) Leronlimab
4) TAK-779
5) Anibamine
6) Met-CCL5
7) Aplaviroc (discontinued due to hepatotoxicity)
saponin or DT-13 9) siRNA and zinc finger nuclease (ZFN)
10) OTR4120 & OTR4131
11) INCB9471 (discontinued after P2 trial for HIV)
12) Cinicriviroc or TBR-652 (completed Phase IIb for HIV and currently being tested in NASH)
(1)
(0)
Please do your own due diligence. All my posts and comments are not to be considered investment advice.
Scroll down for more posts ▼
